{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:05Z","timestamp":1790720345764,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T14:09:43Z","timestamp":1531922983000},"page":"322-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Integrating novel systemic therapies for the treatment of mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.beha.2018.07.007_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.07.007_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib5","first-page":"725","volume":"vol. 63","author":"Bunn","year":"1979","journal-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer treatment reports"},{"issue":"7","key":"10.1016\/j.beha.2018.07.007_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6 Pt 1","key":"10.1016\/j.beha.2018.07.007_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"31","key":"10.1016\/j.beha.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin OncolOff J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib9","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.beha.2018.07.007_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/archderm.1987.01660300079016","article-title":"Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy","volume":"123","author":"Vonderheid","year":"1987","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib16","first-page":"93","article-title":"Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides","volume":"1","author":"Simoni","year":"1987","journal-title":"J Biol Regul Homeost Agents"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.007_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/BTT.S4169","article-title":"Long-term pegylated interferon-alpha and its potential in the treatment of melanoma","volume":"3","author":"Dummer","year":"2009","journal-title":"Biol Targets & Ther"},{"issue":"11","key":"10.1016\/j.beha.2018.07.007_bib19","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma","volume":"31","author":"Schiller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib20","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib21","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.beha.2018.07.007_bib22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10094","key":"10.1016\/j.beha.2018.07.007_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.007_bib27","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.4049\/jimmunol.174.10.5968","article-title":"Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells","volume":"174","author":"Maeda","year":"2005","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.007_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1 Pt 1","key":"10.1016\/j.beha.2018.07.007_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.beha.2018.07.007_bib33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"issue":"21","key":"10.1016\/j.beha.2018.07.007_bib34","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2018.07.007_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V130.Suppl_1.817.817","article-title":"Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the phase III MAVORIC study","volume":"130","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/10428194.2017.1361022","article-title":"Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy","volume":"59","author":"Duvic","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"29","key":"10.1016\/j.beha.2018.07.007_bib38","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.007_bib40","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"14","key":"10.1016\/j.beha.2018.07.007_bib41","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Canc Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.beha.2018.07.007_bib43","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.007_bib44","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620716636541","article-title":"Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential","volume":"7","author":"Duvic","year":"2016","journal-title":"Therapeut Adv Hematol"},{"key":"10.1016\/j.beha.2018.07.007_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3697.3697","article-title":"Correlation of target molecule expression and overall response in refractory cutaneous T-cell lymphoma patients dosed with mogamulizumab (KW-0761), a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4)","volume":"120","author":"Duvic","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2018.07.007_bib47","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.07.007_bib48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Canc Sci"},{"issue":"Suppl","key":"10.1016\/j.beha.2018.07.007_bib50","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1385\/MO:19:2S:S27","article-title":"Alemtuzumab in T-cell malignancies","volume":"19","author":"Dearden","year":"2002","journal-title":"Med Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.007_bib51","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"vol. 50","author":"Querfeld","year":"2009","journal-title":"Leukemia & lymphoma"},{"issue":"117","key":"10.1016\/j.beha.2018.07.007_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.beha.2018.07.007_bib53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.007_bib55","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","article-title":"Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides","volume":"39","author":"Saleh","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.007_bib58","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s004320000178","article-title":"Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up","volume":"127","author":"Wollina","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.beha.2018.07.007_bib62","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.007_bib63","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2018.07.007_bib64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.beha.2018.07.007_bib65","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.007_bib67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","article-title":"2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma","volume":"80","author":"Saven","year":"1992","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib68","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.det.2015.05.009","article-title":"Methotrexate and pralatrexate","volume":"33","author":"Wood","year":"2015","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib69","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.007_bib70","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.007_bib71","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","article-title":"Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers","volume":"64","author":"Izbicka","year":"2009","journal-title":"Canc Chemother Pharmacol"},{"issue":"18","key":"10.1016\/j.beha.2018.07.007_bib72","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.beha.2018.07.007_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428199809057618","article-title":"Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP","volume":"31","author":"Fierro","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.beha.2018.07.007_bib74","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2018.07.007_bib75","first-page":"553","article-title":"ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients","volume":"5","author":"Mebazaa","year":"2005","journal-title":"Hematol J Off J Eur Haematol Assoc"},{"issue":"2","key":"10.1016\/j.beha.2018.07.007_bib76","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2018.07.007_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1749-6632.2001.tb03718.x","article-title":"Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival","volume":"941","author":"Russell-Jones","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.beha.2018.07.007_bib78","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0889-8588(03)00114-X","article-title":"High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma","volume":"17","author":"Oyama","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"issue":"8","key":"10.1016\/j.beha.2018.07.007_bib79","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.beha.2018.07.007_bib80","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.007_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hon.2162","article-title":"Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome","volume":"34","author":"Shiratori","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2018.07.007_bib82","doi-asserted-by":"crossref","unstructured":"Bagot M, Porcu P, Ram Wolff C, Khodadoust M, William B, Battistella M, et al. IPH4102, the first-in-class anti-KIR3DL2 mAb, is safe and clinically active in advanced cutaneous T-cell lymphoma (CTCL) patients: results from the dose-escalation part of the IPH4102-101 phase I study. . European Organisation for Research and Treatment of Cancer: Cutaneous Lymphoma Task Force 2017.","DOI":"10.1016\/j.ejca.2018.07.282"},{"issue":"8","key":"10.1016\/j.beha.2018.07.007_bib83","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.007_bib84","doi-asserted-by":"crossref","first-page":"a181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2018.07.007_bib85","series-title":"Trials.gov. C. A phase 1\/2 trial of durvalumab (medi 4736) when given as a single agent or in combination with lenalidomide in patients with relapsed\/refractory peripheral t cell lymphoma including cutaneous T cell lymphoma","year":"2017"},{"issue":"26","key":"10.1016\/j.beha.2018.07.007_bib86","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2018.07.007_bib87","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:28:46Z","timestamp":1661632126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300264"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating novel systemic therapies for the treatment of mycosis fungoides and S\u00e9zary syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}